發(fā)布時(shí)間：2018-05-05 20:25

  本文選題：天麻素 + 卡馬西平　； 參考：《遼寧中醫(yī)雜志》2017年09期

【摘要】：目的:探討天麻素聯(lián)合卡馬西平治療腦梗死后繼發(fā)癲癇的臨床療效。方法:選取2011年4月—2016年9月該院收治的腦梗死后繼發(fā)癲癇的患者86例為研究對(duì)象,采用隨機(jī)數(shù)字表法分為治療組與對(duì)照組,對(duì)照組患者給予卡馬西平治療,治療組患者給予天麻素聯(lián)合卡馬西平治療的基礎(chǔ)上加用中醫(yī)辨證治療,對(duì)比兩組患者的臨床療效、腦電圖改善情況,在治療前后檢測(cè)患者白細(xì)胞介素-1β(IL-1β)、D-二聚體(D-D)及腫瘤壞死因子-α(TNF-α)的水平變化,并觀察兩組患者不良反應(yīng)發(fā)生情況。結(jié)果:治療組與對(duì)照組的總有效率分別為93.02%、76.74%,兩組相比,治療組總有效率明顯升高(P0.05);治療組與對(duì)照組腦電圖改善率分別為90.70%、81.39%,兩組相比,治療組腦電圖改善率明顯升高(P0.05);與治療前對(duì)比,治療后治療組與對(duì)照組患者的IL-1β、D-D、TNF-α水平均明顯降低(P0.05),且治療組患者IL-1β、D-D、TNF-α水平改善程度優(yōu)于對(duì)照組(P0.05);治療組與對(duì)照組的不良反應(yīng)發(fā)生率分別11.63%、13.95%,兩組不良反應(yīng)發(fā)生率對(duì)比無顯著差異(P0.05)。結(jié)論:天麻素聯(lián)合卡西馬平治療的基礎(chǔ)上加用中醫(yī)辨證治療腦梗后繼發(fā)癲癇可顯著提高臨床療效,改善腦電圖狀況,值得推廣應(yīng)用。
[Abstract]:Objective: to investigate the clinical effect of Gastrodin combined with carbamazepine in the treatment of secondary epilepsy after cerebral infarction. Methods: 86 patients with secondary epilepsy after cerebral infarction were selected from April 2011 to September 2016. The patients were randomly divided into two groups: treatment group and control group. Patients in control group were treated with carbamazepine. The patients in the treatment group were treated with Gastrodin combined with carbamazepine plus TCM syndrome differentiation. The clinical efficacy and the improvement of EEG were compared between the two groups. Before and after treatment, the levels of IL-1- 尾 -IL-1 尾 -D-dimer and tumor necrosis factor- 偽 (TNF- 偽) were detected, and the adverse reactions of the two groups were observed. Results: the total effective rates of the treatment group and the control group were 93.02 and 76.74, respectively. Compared with the two groups, the total effective rate of the treatment group was significantly higher than that of the control group, and the improvement rate of EEG in the treatment group and the control group was 90.70 and 81.39, respectively. The improvement rate of EEG in treatment group was significantly higher than that before treatment. After treatment, the levels of IL-1 尾 -D-DnTNF- 偽 in the treatment group and the control group were significantly lower than those in the control group, and the improvement degree of the IL-1 尾 -D-DNF- 偽 level in the treatment group was better than that in the control group, and the incidence of adverse reactions in the treatment group and the control group was 11.63 ~ 13.95, respectively. There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion: on the basis of Gastrodin combined with Cassemapine therapy combined with TCM syndrome differentiation in the treatment of secondary epilepsy after cerebral infarction can significantly improve the clinical efficacy and improve the state of electroencephalogram which is worth popularizing.
【作者單位】： 云南省第一人民醫(yī)院神經(jīng)內(nèi)科;
【基金】：云南省衛(wèi)生科技計(jì)劃項(xiàng)目(2016NS223)
【分類號(hào)】：R742.1;R743.33

【相似文獻(xiàn)】

相關(guān)期刊論文 前5條

1 李惠玲;中西醫(yī)結(jié)合治療中風(fēng)后繼發(fā)癲癇28例臨床觀察[J];四川中醫(yī);2005年01期

2 李曉巖;;中西醫(yī)結(jié)合治療腦血管繼發(fā)癲癇30例臨床療效觀察[J];中國(guó)衛(wèi)生產(chǎn)業(yè);2012年08期

3 秦遠(yuǎn)文;;中西醫(yī)結(jié)合治療30例腦血管繼發(fā)癲癇的臨床療效觀察[J];現(xiàn)代診斷與治療;2014年10期

4 秦遠(yuǎn)文;;中西醫(yī)結(jié)合治療腦血管繼發(fā)癲癇的臨床療效觀察[J];航空航天醫(yī)學(xué)雜志;2014年07期

5 徐莉;;中西醫(yī)結(jié)合治療腦梗死繼發(fā)癲癇7例[J];中國(guó)中醫(yī)藥現(xiàn)代遠(yuǎn)程教育;2013年02期

，

本文編號(hào)：1849174